Pharmaceutical giant Eli Lilly (LLY) has reported fourth-quarter 2025 financial results that blew past Wall Street forecasts.
The Indiana-based company announced earnings per share (EPS) of $7.54 U.S., which was far ahead of the $6.67 U.S. expected among analysts.
Revenue in the final months of last year totaled $19.29 billion U.S., which easily topped the $17.96 billion U.S. expected on Wall Street.
Management attributed the strong print to rising sales of its blockbuster weight-loss drug Zepbound and diabetes treatment Mounjaro.
Eli Lilly’s forward guidance was equally strong, with the pharmaceutical company saying it expects 2026 revenue of $80 billion U.S. to $83 billion U.S.
Analysts had expected revenue of $77.62 billion U.S. for all of this year.
Eli Lilly also forecast full-year earnings of $33.50 U.S. to $35 U.S. per share. That too was ahead of the $33.23 U.S. anticipated on Wall Street.
The strong results and outlook come months before Eli Lilly launches a pill version of its weight-loss drug, which is expected to be another bestselling medication for the company.
Currently, Zepbound is taken by injection and a pill version is expected to be more palatable to consumers.
Eli Lilly’s raised guidance stands in stark contrast to the outlook of rival pharma giant Novo Nordisk (NVO).
Novo Nordisk says that it is struggling with lower prices in the U.S. following a landmark deal it struck with U.S. President Donald Trump to cut obesity and diabetes drug costs.
Novo Nordisk recently warned that its sales and profits are likely to decline this year as prices fall in the U.S. and exclusivity expires for its blockbuster obesity and diabetes drugs in China.
Eli Lilly said that its diabetes medication Mounjaro generated $7.41 billion U.S. in revenue for Q4 2025, up 110% from the same period a year earlier.
Weight-loss drug Zepbound posted $4.20 billion U.S. in Q4 revenue, up 122% from a year earlier as demand rose while prices fell.
Analysts were expecting $3.91 billion U.S. in sales for Zepbound at the end of last year.
LLY stock has risen 22% over the last 12 months to trade at $1,003.46 U.S. per share.
Related Stories
